Study 329 was a clinical trial conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI antidepressantmarketed as Paxil and Seroxat, in treating depressed teenagers.
It concluded that paroxetine is “generally well tolerated and effective for major depression in adolescents.” In 2001, the study was published in theJournal of the American Academy of Child and Adolescent Psychiatry.
Study 329 was funded by GlaxoSmithKline (GSK), the drug’s manufacturer.
The company greatly exaggerated the effectiveness of the drug, and downplayed how dangerous it is for teens.
Unfortunately, Study 329 is not an outlier: drug studies have long been known to be flawed, mainly because testing is conducted by the very entities that stand to profit from sales of the medications – the drug manufacturers.
Another recent study exposed just how pervasive and serious the problem is.
Delivered by The Daily Sheeple
No comments:
Post a Comment